Evidence map›Paper›PMID 29270806›Full record

ArticleArchives of toxicology2018

Mesenchyme-derived factors enhance preneoplastic growth by non-genotoxic carcinogens in rat liver.

Marzieh Nejabat, Teresa Riegler, Tabea Reitinger, Sandra Subosits, Michael Römer, Johannes Eichner, Martin Bilban, Andreas Zell, Wolfgang W Huber, Rolf Schulte-Hermann and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Marzieh NejabatDepartment of Medicine I, Comprehensive Cancer Center, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria.
Teresa RieglerDepartment of Medicine I, Comprehensive Cancer Center, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria.
Tabea ReitingerDepartment of Medicine I, Comprehensive Cancer Center, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria.
Sandra SubositsDepartment of Medicine I, Comprehensive Cancer Center, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria.
Michael RömerCenter of Bioinformatics Tübingen (ZBIT), University of Tübingen, Tübingen, Germany.
Johannes EichnerCenter of Bioinformatics Tübingen (ZBIT), University of Tübingen, Tübingen, Germany.
Martin BilbanDepartment of Laboratory Medicine and Core Facility Genomics, Medical University of Vienna, Vienna, Austria.
Andreas ZellCenter of Bioinformatics Tübingen (ZBIT), University of Tübingen, Tübingen, Germany.
Wolfgang W HuberDepartment of Medicine I, Comprehensive Cancer Center, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria.
Rolf Schulte-HermannDepartment of Medicine I, Comprehensive Cancer Center, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria.
Bettina Grasl-KrauppDepartment of Medicine I, Comprehensive Cancer Center, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria. bettina.grasl-kraupp@meduniwien.ac.at.ORCID http://orcid.org/0000-0003-4889-6531
Comprehensive Cancer Center Vienna · ATUniversity of Tübingen · DEMedical University of Vienna · AT

Funding

IMI Nr 115001
6 · The paper itself

Abstract

Many frequently prescribed drugs are non-genotoxic carcinogens (NGC) in rodent liver. Their mode of action and health risks for humans remain to be elucidated. Here, we investigated the impact of two model NGC, the anti-epileptic drug phenobarbital (PB) and the contraceptive cyproterone acetate (CPA), on intrahepatic epithelial-mesenchymal crosstalk and on growth of first stages of hepatocarcinogenesis. Unaltered hepatocytes (HC) and preneoplastic HC (HC

Indexed as

AnimalsApoptosisCarcinogenicity TestsCarcinogensCells, CulturedCyproterone AcetateDNA ReplicationFemaleHepatocytesIntercellular Signaling Peptides and ProteinsLiverMaleMesodermPhenobarbitalPrimary Cell CultureRatsCarcinogensCyproterone AcetateIntercellular Signaling Peptides and ProteinsPhenobarbitalCyproterone acetateHepatocarcinogenesisLiver mesenchymeNon-genotoxic hepatocarcinogenesisPhenobarbital

Identifiers

PMID29270806
PMCPMC5818586
OpenAlexW2777610604

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.